Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.250 +0.080 (+6.84%)
Official Closing Price Updated: 6:30 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Preview: Lineage Cell Therapeutics
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
Via TheNewswire.com
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
By David Willey, Benzinga 
Via News Direct
Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
Via Benzinga
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
121 Stocks That Hit Their 52-Week Low
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa
From Lineage Cell Therapeutics, Inc.
Via Business Wire
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. 
Via Benzinga
The Three Best Anti-Aging Stocks to Buy in September
These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments 
Via InvestorPlace
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q2, Lineage Cell Therapeutics's (AMEX:LCTX) reported sales totaled $4.55 million. Despite a 4.38% increase in earnings, the company posted a loss of $6.78... 
Via Benzinga
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Recap: Lineage Cell Therapeutics Q2 Earnings
  Lineage Cell Therapeutics (AMEX:LCTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades 
Via Benzinga
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics: Q1 Earnings Insights
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Preview: Lineage Cell Therapeutics
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.